With the help of new technology, the researchers of the University of Turku have gained more detailed information on the diversity of the human lymphatic system than before. The research results can help to understand the human defence mechanisms on the molecular level even better than before. Several cancers, such as breast cancer and head and neck cancers, spread primarily via the lymphatic system.
Researchers from Turku Bioscience Centre Identified Novel Oncogenic Function for Receptor Linked with Alzheimer’s Disease
Common and rare SORLA single nucleotide polymorphisms have been associated with the development of Alzheimer’s disease. So far, SORLA has been mainly studied in neurons, but the new study focused on the role of SORLA in cancer cells. Led by Academy Professor Johanna Ivaska, the research group observed that SORLA was highly expressed in HER2 positive cancers. Removing SORLA from cancer cells severely impaired the oncogenic fitness of HER2 positive cancers.
According to a new research, circulating tumor DNA can be used to detect treatment options for ovarian cancer patients who don’t benefit from chemotherapy.
Cancer Researchers at University of Turku Managed to Correct Decades-old Misconception on White Blood Cell Trafficking to Spleen
Contrary to prior belief, the white blood cells enter the spleen primarily via vessels in the red pulp. The research results change thoroughly our perception of the spleen producing antibodies vital for the human body.
Medicity is the research laboratory of the Medical Faculty of Universuty of Turku. Medicity provides the laboratory, infrastructure, and office space for altogether about 100 scientists and technicians. The basic goal of Medicity is to provide the researchers with a stimulating research and training environment and produce high-quality research in biomedicine and translational medicine.
Developed by researchers at the University of Turku, an immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumours in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.